ResearcherKurume UniversityNo recent work listed
Tomoyuki Ushijima
Matched on OpenAlex author ID A5103838162. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 5
- Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-023-46924-0↗
- A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Co-author DOI 10.1097/md.0000000000026052↗
- Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00795-019-00218-5↗
- A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. Co-author DOI 10.4103/eus.eus_58_17↗
- Evaluation of endoscopic cytological diagnosis of unresectable pancreatic cancer prior to and after the introduction of endoscopic ultrasound-guided fine-needl… Co-author DOI 10.3892/mco.2014.277↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yoshinobu Okabe · 5 shared papers, 2014–2023 · strength 0.45
- Paper Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients wit… DOI 10.1038/s41598-023-46924-0↗
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. DOI 10.4103/eus.eus_58_17↗
- Masaru Fukahori · 3 shared papers, 2019–2023 · strength 0.33
- Paper Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients wit… DOI 10.1038/s41598-023-46924-0↗
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Takuji Torimura · 3 shared papers, 2018–2021 · strength 0.27
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. DOI 10.4103/eus.eus_58_17↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Keisuke Miwa · 2 shared papers, 2021–2023 · strength 0.26
- Paper Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients wit… DOI 10.1038/s41598-023-46924-0↗
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Yoshiki Naito · 3 shared papers, 2014–2021 · strength 0.24
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. DOI 10.4103/eus.eus_58_17↗
- Paper Evaluation of endoscopic cytological diagnosis of unresectable pancreatic cancer prior to and after the introduction of… DOI 10.3892/mco.2014.277↗
- Takahiko Sakaue · 2 shared papers, 2019–2021 · strength 0.20
- Paper A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. DOI 10.1097/md.0000000000026052↗
- Paper Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic … DOI 10.1007/s00795-019-00218-5↗
- Junichi Nakazawa · 1 shared paper, 2023 · strength 0.14
- Kenji Mitsugi · 1 shared paper, 2023 · strength 0.14
- Norio Ureshino · 1 shared paper, 2023 · strength 0.14
- Shiho Arima · 1 shared paper, 2023 · strength 0.14
- Futa Koga · 1 shared paper, 2023 · strength 0.14
- Taro Shibuki · 1 shared paper, 2023 · strength 0.14
- Mototsugu Shimokawa · 1 shared paper, 2023 · strength 0.14
- Taiga Otsuka · 1 shared paper, 2023 · strength 0.14
- Tsuyoshi Shirakawa · 1 shared paper, 2023 · strength 0.14
- Yasushi Ide · 1 shared paper, 2023 · strength 0.14
- Azusa Komori · 1 shared paper, 2023 · strength 0.14
- Hiroki Taguchi · 1 shared paper, 2023 · strength 0.14
- Yusuke Ishida · 2 shared papers, 2014–2018 · strength 0.12
- Hiroto Ishikawa · 1 shared paper, 2018 · strength 0.08
- Jun Akiba · 1 shared paper, 2018 · strength 0.08
- Hironori Koga · 1 shared paper, 2019 · strength 0.08
- Toru Nakamura · 1 shared paper, 2019 · strength 0.08
- Michio Sata · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.